20 articles
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
A Phase 1/2 NCI trial tested PANVAC vaccinia and fowlpox vaccines plus immune booster sargramostim in advanced colorectal, breast, and ovarian cancers.
A completed French trial explores how gut and airway microbiota, blood, and sputum biomarkers relate to immunotherapy outcomes in metastatic NSCLC.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.
A completed exploratory trial evaluates whether a specialized compression garment can reduce discomfort and improve quality of life in pelvic lymphedema patients.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
New viral therapy ASP9801 targets solid tumors directly, potentially offering hope for patients with advanced metastatic cancer.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
MD Anderson researchers evaluated vemurafenib, cetuximab, and irinotecan together to find the optimal dose and safety profile for advanced solid tumors.
A Swiss feasibility trial tests digital mindfulness-based cancer recovery, tracking psychosocial outcomes, medication use, and biological markers.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
French researchers studied how tiny cellular packages called exosomes may help melanoma cells resist treatment and spread throughout the body.
A completed NCI trial evaluated advanced imaging and breast duct lavage in women with BRCA1/BRCA2 mutations to improve early cancer detection.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
